Faeth Therapeutics (FTH) executive compensation, 2026 proxy

John Celebi, Former President and Chief Executive Officer, was paid $1.3M in 2025, up 6% from $1.2M the year before.

Filed
April 27, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
5
CEO total pay
$1.3M+6% vs prior year
CEO 2025 Total Compensation
$1,260,500Includes termination severance and benefits.
CEO Target Bonus Percentage
55%Of base salary.
Acquisition Consideration
$200MFrom 2026 Private Placement.

How Celebi was paid

$1.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary38%Option awards11%All other compensation51%

Named executive officers

ExecutiveTotal
John CelebiFormer President and Chief Executive Officer$1,260,500
Christopher W. GerryPresident and General Counsel$434,600
Stephanie KrebsFormer Chief Business Officer$730,701
Edward van der Horst, Ph.D.Former Chief Scientific Officer$749,190
Josiah CraverSVP, Finance$409,710

What changed and why

  • $1.3MFormer CEO John Celebi received total compensation of $1,260,500 in 2025, compared to $1,183,643 in 2024.
  • No annual bonuses were paid to any named executive officer for 2025 due to strategic alternatives and the Acquisition.
  • John Celebi, Stephanie Krebs, and Edward van der Horst all departed as executive officers effective November 14, 2025.
  • Termination-related severance and health insurance reimbursements significantly increased All Other Compensation for departing executives in 2025.
  • Stock option awards were granted to executives in February 2025 under the 2021 Plan.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.